Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2D6 | P10635 | 3/20 | 0.61 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.54 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.54 |
| ▸ | OPRL1 | P41146 | 1/20 | 0.53 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.52 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.52 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.52 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.51 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.51 |
| ▸ | POLB | P06746 | 1/20 | 0.51 |
| ▸ | GAA | P10253 | 1/20 | 0.51 |
| ▸ | MEN1 | O00255 | 1/20 | 0.51 |
| ▸ | MAPT | P10636 | 1/20 | 0.50 |
| ▸ | NPFFR1 | Q9GZQ6 | 1/20 | 0.50 |
| ▸ | NPFFR2 | Q9Y5X5 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL6543346 | 0.98 | CYP2D6 (0.59) | CYP2D6L3MBTL1ALDH1A1MAPK1OPRL1 | |
| SCHEMBL8876545 | 0.93 | SIGMAR1 (0.56) | CYP2D6L3MBTL1ALDH1A1MAPK1CHRM2 | |
| SCHEMBL4631263 | 0.88 | CYP2D6 (0.56) | CYP2D6L3MBTL1ALDH1A1MAPK1OPRL1 | |
| SCHEMBL17775632 | 0.87 | P4HB (0.58) | CYP2D6L3MBTL1ALDH1A1MAPK1KMT2A | |
| Hydrochloric Acid SCHEMBL20212096 | 0.86 | POLB (0.56) | CYP2D6L3MBTL1ALDH1A1MAPK1OPRL1 | |
| SCHEMBL14000284 | 0.84 | LMNA (0.48) | CYP2D6ALDH1A1MAPK1OPRL1SMN1; SMN2 | |
| SCHEMBL18203100 | 0.84 | L3MBTL1 (0.63) | CYP2D6L3MBTL1ALDH1A1MAPK1KMT2A | |
| SCHEMBL4629950 | 0.84 | L3MBTL1 (0.53) | CYP2D6L3MBTL1ALDH1A1MAPK1OPRL1 | |
| Bromide SCHEMBL7749201 | 0.82 | L3MBTL1 (0.52) | CYP2D6L3MBTL1ALDH1A1MAPK1OPRL1 | |
| SCHEMBL4864670 | 0.82 | L3MBTL1 (0.77) | L3MBTL1ALDH1A1MAPK1KMT2ASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180155343-A1 | SPIRO-ISOQUINOLINE-3,4'-PIPERIDINE COMPOUNDS HAVING ACTIVITY AGAINST PAIN | ESTEVE PHARMACEUTICALS, S.A. (ES) | 2018-06-07 | — | — | US | disclosed |
| CN-101230008-A | Substituted heterocyclic compounds, process for their preparation and pharmaceutical compositions containing them | SANOFI SYNTHELABO (FR) | 2008-07-30 | — | — | CN | disclosed |
| EP-1923391-A1 | Substituted heterocyclic compounds, method for preparing same and pharmaceutical compositions containing them. | sanofi-aventis (FR) | 2008-05-21 | — | — | EP | disclosed |
| CN-1295221-C | Substituted heterocyclic compounds | SANOFI AVENTIS (FR) | 2007-01-17 | — | — | CN | disclosed |
| CN-1293063-C | Substituted heterocyclic compounds, process for their preparation and pharmaceutical compositions containing them | SANOFI SYNTHELABO (FR) | 2007-01-03 | — | — | CN | disclosed |
| CN-1821241-A | Substituted heterocyclic compounds, preparation method therefor and pharmaceutical compositions containing same | SANOFI SA (FR) | 2006-08-23 | — | — | CN | disclosed |
| EP-1688416-A1 | Substituted heterocyclic compounds, their process of preparation and pharmaceutical compositions containing them | Sanofi-Aventis (FR) | 2006-08-09 | — | — | EP | disclosed |
| CN-1636983-A | Substituted heterocyclic compounds | SANOFI AVENTIS (FR) | 2005-07-13 | — | — | CN | disclosed |
| CN-1202093-C | Substituted heterocyclic compounds | SANOFI AVENTIS (FR) | 2005-05-18 | — | — | CN | disclosed |
| CN-1179954-C | Substituted heterocyclic compounds, process for their preparation and pharmaceutical compositions containing them | ��ŵ�Ѻϳ�ʵ���� | 2004-12-15 | — | — | CN | disclosed |
| EP-1156049-A1 | Substituted heterocyclic compounds, their process of preparation and pharmaceutical compositions containing them | SANOFI-SYNTHELABO (FR) | 2001-11-21 | — | — | EP | disclosed |
| CN-1321634-A | Substd heterocyclic compounds preparing method thereof and pharmaceutical composition contg. them | SANOFI SYNTHESIZING LAB (FR) | 2001-11-14 | — | — | CN | disclosed |
| CN-1321639-A | Substituted heterocyclic compounds, process for their preparation and pharmaceutical compositions containing them | SANOFI SYNTHESIZING LAB (FR) | 2001-11-14 | — | — | CN | disclosed |
| EP-1019373-A1 | NOVEL HUMAN NK 3? RECEPTOR-SELECTIVE ANTAGONIST COMPOUNDS, METHOD FOR OBTAINING THEM AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | SANOFI-SYNTHELABO (FR) | 2000-07-19 | — | — | EP | disclosed |
| CN-1172483-A | Substituted heterocyclic compounds, process for their preparation and pharmaceutical compositions containing them | SANOFI SA (FR) | 1998-02-04 | — | — | CN | disclosed |
| EP-0807111-A1 | SUBSTITUTED HETEROCYCLIC COMPOUNDS, PREPARATION METHOD THEREFOR AND PHARMACEUTICAL COMPOSITIONS CONTAINING SAME | SANOFI (FR) | 1997-11-19 | — | — | EP | disclosed |
| WO-1997010211-A1 | NOVEL HUMAN NK3 RECEPTOR-SELECTIVE ANTAGONIST COMPOUNDS, METHOD FOR OBTAINING THEM AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | SANOFI (FR) | 1997-03-20 | — | — | WO | disclosed |
| WO-1996023787-A1 | SUBSTITUTED HETEROCYCLIC COMPOUNDS, PREPARATION METHOD THEREFOR AND PHARMACEUTICAL COMPOSITIONS CONTAINING SAME | SANOFI (FR) | 1996-08-08 | — | — | WO | disclosed |
| EP-0700386-A1 | NEUROKININ RECEPTOR ANTAGONISTS | SANOFI (FR) | 1996-03-13 | — | — | EP | disclosed |
| WO-1995026338-A1 | NEUROKININ RECEPTOR ANTAGONISTS | SANOFI (FR) | 1995-10-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180155343-A1 | SPIRO-ISOQUINOLINE-3,4'-PIPERIDINE COMPOUNDS HAVING ACTIVITY AGAINST PAIN | OPRK1, OPRD1, SIGMAR1 | CYP2D6 593/4885L3MBTL1 4833/4885ALDH1A1 608/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.